Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials
ConclusionsThe increased cardiovascular risks associated with diclofenac initiation were higher than for other older COX-2 inhibitors (meloxicam/etodolac) and comparable to coxibs (celecoxib/etoricoxib).
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Celebrex | Denmark Health | Diclofenac | Drugs & Pharmacology | Etodolac | Heart | Meloxicam | Mobic | Study | Voltaren | Women